Login to Your Account

FDA Panel Vote on Anemia Drugs Gets Mixed Reviews

By Donna Young

Thursday, September 13, 2007
While Amgen and Ortho Biotech tried to put a positive spin on Tuesday's votes by a federal advisory panel about anemia drugs, the outcome of the meeting is not as benign as it appeared for the future of the drugs, predicted Lazard Capital Markets analyst Joel Sendek. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription